Scarica l'app Stockscreener
2.73
6.83%
-0.20
Pre-mercato:
2.88
0.15
+5.49%
Cervomed Inc Borsa (CRVO) Ultime notizie
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - stocktwits.com
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Canada
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - moomoo.com
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - moomoo.com
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget
CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView
CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView
CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash - Stock Titan
CRVO: Neflamapimod progresses to Phase 3 for DLB, with strong cash position and key milestones ahead - TradingView
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CervoMed Inc. (CRVO) Edges Lower to $2.77 as Shares Consolidate Within Tight Trading RangeADD Alert - dars.gov.et
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
CervoMed to discuss neflamapimod progress at Ca... - Pluang
CervoMed Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
CervoMed granted UK Innovation Passport for neflamapimod in dementia with Lewy bodies - TradingView
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - The Manila Times
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CervoMed Inc (CRVO) Cash Flow - TradingKey
CervoMed Inc (CRVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVO|CervoMed Inc|Price:2.690|Chg%:+0.030 - TradingKey
CRVO|CervoMed Inc|Price:2.640|Chg%:-0.020 - TradingKey
CervoMed Inc (CRVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CervoMed Inc (CRVO) Institutional Confidence - TradingKey
CervoMed Inc (CRVO) Income Statement - TradingKey
CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO - TradingView
CRVO|CervoMed Inc|Price:2.660|Chg%:-0.010 - TradingKey
CervoMed Inc. (CRVO) Q1 2026 Earnings: EPS Misses Estimates as Clinical Investment ContinuesEarnings Acceleration Picks - dars.gov.et
Matt Winton Says Most Biotechs Are Not the Best to Launch Their Own Drugs — and That’s a Strength, Not a Failure - finance.biggo.com
Insiders the Biggest Winners as CervoMed Inc.'s (NASDAQ:CRVO) Market Cap Rises to US$151m - 富途牛牛
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target - Investing.com UK
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target By Investing.com - Investing.com South Africa
CRVO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
HC Wainwright reiterates Buy on CervoMed, maintains $25 target - scanx.trade
CervoMed Inc. Announces New Clinical Data for Neflamapimod in Dementia with Lewy Bodies at AAIC 2026 - Minichart
CervoMed (NASDAQ: CRVO) highlights DLB trial data and Phase 3 plans - Stock Titan
CervoMed selects 50 mg Phase 3 dose - grafa.com
CervoMed presents dementia drug data at AAIC 2026 conference By Investing.com - Investing.com Nigeria
CervoMed Inc. Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in Treatment of Dementia with Lewy Bodies - marketscreener.com
CervoMed presents dementia drug data at AAIC 2026 conference - Investing.com
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - The Manila Times
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):